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Object: Aneurysmal subarachnoid hemorrhage (aSAH) is a common cause of death or 
long-term disability. Despite advances in neurocritical care, there is still only a very limited 
ability to monitor the development of secondary brain injury or to predict neurological 
outcome after aSAH. Soluble urokinase-type plasminogen activator receptor (suPAR) 
has shown potential as a prognostic and as an inflammatory biomarker in a wide range 
of critical illnesses since it displays an association with overall immune system activation. 
This is the first time that suPAR has been evaluated as a prognostic biomarker in aSAH.
Methods: In this prospective population-based study, plasma suPAR levels were mea-
sured in aSAH patients (n = 47) for up to 5 days. suPAR was measured at 0, 12, and 
24 h after patient admission to the intensive care unit (ICU) and daily thereafter until he/
she was transferred from the ICU. The patients’ neurological outcome was evaluated 
with the modified Rankin Scale (mRS) at 6 months after aSAH.
results: suPAR levels (n = 47) during the first 24 h after aSAH were comparable in groups 
with a favorable (mRS 0–2) or an unfavorable (mRS 3–6) outcome. suPAR levels during 
the first 24 h were not associated with the findings in the primary brain CT, with acute 
hydrocephalus, or with antimicrobial medication use during 5-days’ follow-up. suPAR 
levels were associated with generally accepted inflammatory biomarkers (C-reactive 
protein, leukocyte count).
conclusion: Plasma suPAR level was not associated with either neurological outcome 
or selected clinical conditions. While suPAR is a promising biomarker for prognostication 
in several conditions requiring intensive care, it did not reveal any value as a prognostic 
biomarker after aSAH.
Keywords: aneurysmal subarachnoid hemorrhage, biomarkers, neurological outcome, secondary brain injury, 
soluble urokinase-type plasminogen activator receptor, neuroinflammation
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inTrODUcTiOn
Urokinase plasminogen activator receptor (uPAR) (CD87) is 
present on various immunologically active cells, and its expres-
sion becomes elevated by inflammatory conditions and ischemic 
diseases (1, 2). The soluble form [soluble urokinase-type plas-
minogen activator receptor (suPAR)] in serum or plasma has 
emerged as an inflammatory biomarker capable of reflecting 
overall immune system activation (3, 4).
Previously, it has been shown that uPAR expression is induced 
in cerebral ischemia (5) and traumatic brain injury (6). Moreover, 
it has been claimed that uPAR may further augment cerebral 
injury (7). The induction of uPAR expression on the cell surface 
is believed to increase the levels of the soluble form of uPAR (8). 
Previously, suPAR has been shown to have predictive value in 
acutely, critically ill patients (9–13), including those who have 
suffered brain trauma (14). However, as far as we are aware, 
suPAR concentrations have not been evaluated as a prognostic 
biomarker in patients with subarachnoid hemorrhage.
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastat-
ing disease causing long-term disability and up to 50% mortality 
(15). A significant proportion of the patients are young and 
previously healthy in comparison to individuals suffering other 
types of strokes (16). The main causes for poor prognosis are 
early brain injury and delayed cerebral ischemia (DCI), which 
cause permanent neurological deficits (17–19). The prediction of 
outcome is difficult and unsatisfactory as the secondary injury 
process in aSAH is multifactorial and incompletely understood 
(17, 20).
It is well established that inflammation plays a major role in 
vasospasm and subsequent DCI after aSAH (21, 22). A plethora 
of biomarkers have been studied in aSAH and DCI, e.g., neuron 
and astrocyte-specific markers (e.g., NSE, s100b, and UCHL-1), 
inflammatory biomarkers (e.g., IL-6, HMGB-1), and molecular 
adhesion and extracellular matrix markers (e.g., MMP-9) 
(16, 23–25). However, none of these putative biomarkers has so 
far proved to be useful in clinical decision-making. As ischemic 
events and inflammation are one characteristic feature of aSAH, 
it seemed reasonable to speculate that circulating plasma suPAR 
concentrations would increase during the acute stage after aSAH. 
Therefore, we hypothesized that either the plasma suPAR concen-
tration or alternatively its changes over time could be useful in 
predicting the neurological outcome following aSAH.
MaTerials anD MeThODs
The clinical data and blood samples from this patient cohort have 
been used in a previously published study (25). Following reg-
istration in Clinical Trials (NCT02026596, https://clinicaltrials.
gov) and approval by the institutional ethics committee, we con-
ducted a prospective, observational, single-center clinical study 
in Tampere University Hospital (Tampere, Finland) intensive 
care unit (ICU). The study population consisted of 61 consecu-
tive adult aSAH patients admitted to our tertiary referral center 
during a 10-month period in 2013. Written informed consent 
was obtained from each of the patients or from their next of 
kin. All patients were treated according to standard in-house 
guidelines, which included intravenous nimodipine to prevent 
vasospasm and routine laboratory samples. In the final analyses, 
we chose to exclude those 14 patients with an unknown time of 
onset of symptoms or in whom the suPAR concentration was not 
measured during the first 24 h after the onset of symptoms. By 
including only those 47 patients with a known onset of clinical 
ictus and suPAR measurement during the first 24  h after the 
onset of symptoms, we eliminated the possibility that changes in 
suPAR concentrations would be attributable to different delays to 
hospital admission after aSAH.
The plasma suPAR concentration was measured at 0, 12, and 
24 h after the admission and every 24 h for up to 5 days or until 
the patient was transferred from the ICU. World Federation of 
Neurological Surgeons Grading Scale, Fisher grade, and 6-month 
modified Rankin Scale (mRS) were used to evaluate the sever-
ity of aSAH and neurological recovery as previously described 
(25). The incidence of acute hydrocephalus was defined as the 
need for ventriculostomy on a clinical basis during the first 24 h 
after aSAH. Infection was defined as the need for antimicrobial 
medication during intensive care follow-up period.
As a part of our in-house guideline, an arterial cannula was 
routinely inserted. Blood samples for suPAR were collected 
into EDTA-containing tubes from the arterial cannula and the 
samples were immediately centrifuged for 10 min at 2,000 g at 
room temperature. After centrifugation, the plasma was collected 
and frozen at −70°C. After thawing, plasma suPAR levels were 
measured with a commercially available enzyme-linked immu-
nosorbent assay kit according to the manufacturer’s instructions 
(suPARnostic®, ViroGates, Birkeroed, Denmark). The detection 
limit and inter-assay coefficient of variation were 0.45 ng/ml and 
3.2%, respectively.
Before the statistical analysis, the suPAR measurements were 
divided into consecutive 24 h intervals, starting from the onset of 
symptoms. If suPAR was measured more than once per interval, 
the mean concentration was used. In a subgroup of 22 patients 
who had up to 5-days’ follow-up, we also checked whether the 
patient had been treated for DCI. Initiation of this treatment was 
based on clinical evaluation. Statistical analyses were performed 
with R (version 3.3.2 for Mac Os X). Fisher’s exact test was used 
with the categorical variables. Due to the non-normal distribu-
tion of measured biomarkers, Mann–Whitney U-test was used 
for between-group comparisons. Correlations were evaluated 
with Spearman’s correlation test. Linear regression was used in 
the time interval analyses.
resUlTs
The basic characteristics of the study cohort and the subset of 
patients with 5-day follow-up have been previously reported 
(25). The time course of plasma suPAR concentrations in the 
two groups according to neurological outcome are depicted in 
Figure 1.
Plasma suPAR concentrations during the first 24 h after aSAH 
were comparable in the groups with a favorable (mRS 0–2) and an 
unfavorable (mRS 3–6) outcome (Figure 2A). Similarly, no dif-
ferences were detected in the suPAR levels between those patients 
presenting with severe (WFNS 4–5) vs. non-severe (WFNS 1–3) 
FigUre 1 | soluble urokinase-type plasminogen activator receptor (suPar) levels in all patients and at all time intervals. Values are grouped according 
to whether the patients had a favorable or an unfavorable neurological outcome. Dots represent individual patient values. The line represents group median.
FigUre 2 | soluble urokinase-type plasminogen activator receptor (suPar) levels during the first 24 h after aneurysmal subarachnoid hemorrhage 
between patients (n = 47) with a favorable or an unfavorable neurological outcome (a). suPAR levels at the end of 5-day follow-up between patients 
(n = 22) with a favorable or an unfavorable neurological outcome (B).
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findings in terms of their clinical status on admission (Table 1). 
Furthermore, the plasma suPAR concentration during the first 
24 h was not associated with the findings from the primary brain 
CT (Fisher grade) with acute hydrocephalus or with antimicro-
bial medication during the 5-days’ follow-up (Table 1). Age over 
70 years was a strong predictor of an unfavorable neurological 
outcome, i.e., only one patient over 70  years experienced a 
neurologically favorable outcome (p = 0.037, Table 2).
suPAR was measured daily up to 5 days after the admission 
unless the patient died or was transferred from the ICU. In the 22 
patients in whom we had suPAR concentrations measured up to 
5 days, four patients achieved a favorable neurological outcome 
TaBle 2 | The relationship between neurological outcome and age.
age ≤ 70 age > 70 p-Value
0.037
Modified Rankin Scale (mRS) 0–2 15 1
mRS 3–6 20 11
Fisher’s exact test was used.
TaBle 1 | soluble urokinase-type plasminogen activator receptor 
(suPar) concentrations (n = 47) within 24 h from aneurysmal 
subarachnoid hemorrhage and the association with selected clinical 
conditions.
suPar (ng/ml) Mean sD Median iQr p-Value
Modified Rankin Scale 0.234
0–2 (n = 16) 2.30 0.75 2.21 1.73–2.77
3–6 (n = 31) 2.66 0.96 2.37 2.06–3.05
World Federation of 
Neurological Surgeons 
grading scale
0.803
1–3 (n = 28) 2.59 1.05 2.26 2.00–2.79
4–5 (n = 19) 2.47 0.66 2.41 2.00–2.86
Fisher 0.240
1–2 (n = 14) 2.36 0.93 2.05 1.67–2.78
3–4 (n = 33) 2.61 0.90 2.41 2.07–2.80
Infection 0.402
Yes (n = 14) 2.55 0.64 2.61 2.21–2.88
No (n = 33) 2.53 1.01 2.22 1.92–2.79
Acute hydrocephalus 0.845
Yes (n = 19) 2.54 0.83 2.27 2.09–2.80
No (n = 28) 2.53 0.97 2.34 1.92–2.83
Mann–Whitney U-test was used.
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(mRS 0–2). The linear regression did not detect any statistically 
significant elevation of suPAR levels during the 5-days’ follow-up 
in patients with either a favorable (mRS 0–2) or an unfavorable 
(mRS 3–6) neurological outcome (Figure 3). In addition, at day 
five, plasma suPAR concentrations were comparable in the two 
groups (Figure 2B).
Delayed cerebral ischemia treatment was initiated in 16/22 
patients during the hospital stay in the subgroup in which we 
had at least a 5-day ICU follow-up. Neither DCI treatment nor 
infection or acute hydrocephalus was associated with plasma 
suPAR concentrations (Table 3).
The peak plasma suPAR concentration during the 5 days of 
follow-up was positively correlated with peak levels of C-reactive 
protein (CRP) (p = 0.039) and leukocyte numbers (p = 0.006). 
The plasma suPAR concentration was positively correlated with 
the leukocyte count during the first 24 h (p = 0.049). In contrast, 
suPAR levels were not associated with age (Table 4).
DiscUssiOn
The present study aimed to evaluate the potential prognostic value 
of plasma suPAR concentrations after an aSAH. In contrast to our 
working hypothesis, plasma suPAR did not show any association 
with neurological outcome, survival, acute hydrocephalus, clini-
cal infection, or DCI in our patient cohort.
The inflammatory reaction and increase of systemic inflam-
matory mediators in aSAH is well documented (22, 26). Even 
though substantial evidence is accumulating in the literature 
highlighting the significant role of neuroinflammation in the 
outcome of aSAH, it is still unclear which, if any, inflammatory 
biomarkers can be used to guide clinical decision-making. The 
apparent biphasic nature of the inflammatory response after aSAH 
makes this challenge even more demanding. Neuroinflammation 
seems to have properties, which can be considered in some cases 
as protective, but in others, as deleterious, e.g., depending on 
the magnitude of the response, time-point after the ictus when 
activation of the inflammatory response occurs, and the type of 
cells recruited in the response (27). Hence, it is not surprising 
that there is inconsistency regarding the prognostic value of many 
inflammatory biomarkers such as IL-6 and HMGB1 after aSAH 
(19, 25, 28, 29). Nevertheless, although no biomarker has been 
identified, these studies have increased our understanding of the 
inflammatory process in aSAH and, in fact, also novel inflamma-
tory biomarkers are claimed to have some prognostic potential, 
e.g., toll-like receptor 4 (30).
suPAR is considered as an inflammatory biomarker and 
mediator, a proposal that is well supported in the literature. 
Previously, increased serum or plasma suPAR levels have been 
postulated as a prognostic factor for poor outcome in critically 
ill patients with an inflammatory condition (31). The plasma 
suPAR concentrations in our aSAH cohort were low compared 
to septic and non-septic ICU patients with organ dysfunction 
(32). Nosocomial infections, organ dysfunction, and SIRS are 
frequent after aSAH (33, 34). Although the value of suPAR has 
been verified in infections and organ dysfunction (13, 32, 35), we 
did not detect high levels of suPAR, even later in the course of 
intensive care. One possible confounding factor distinguishing 
aSAH from other acute neurological conditions is that all of our 
patients received nimodipine to prevent DCI. Nimodipine has 
been shown to decrease plasminogen activator inhibitor 1 (PAI-1) 
activity (36). As PAI-1 is the major inhibitor of urokinase plasmi-
nogen activator (uPA), plasminogen activity and fibrinolysis may 
increase as a consequence of decreased PAI-1 activity. UPA can 
cleave the GPI-anchor on cell surface, but since a correct ratio of 
uPA is required for cleavage, it is possible that excess uPA due to 
nimodipine may inhibit the cleavage of suPAR from the cell sur-
face (4, 8). suPAR also displays uPA dose dependence for binding 
to vitronectin (37), which may alter suPAR levels. Furthermore, 
previous reports have described suPAR-fragment release from 
activated neutrophils (38) and inhibition of neutrophil activation 
by two calcium antagonists, felodipine, and nimodipine (39), 
thereby supporting the concept that nimodipine may indeed be 
the factor modifying the suPAR response in our patient cohort. 
This speculative hypothesis and thus the potential direct effect of 
nimodipine on plasma suPAR concentrations could not be further 
tested/evaluated in our patient cohort. Moreover, as nimodipine 
is considered as part of current best practice, it would be unethi-
cal to establish a control group not receiving nimodipine after 
aSAH. Any further experiments to test this hypothesis will need 
to be conducted as preclinical/animal studies.
Overall, the suPAR response, i.e., the increase in the plasma 
concentrations of suPAR observed in this study, was rather 
modest in comparison with that observed in other critically ill 
patients, even though there was biochemically logical correlation 
TaBle 4 | soluble urokinase-type plasminogen activator receptor and its 
association with leukocyte count, c-reactive protein (crP), and age.
spearman rho p-Value
Day 1 (n = 47)
Leukocyte count 0.289 0.049
CRP 0.261 0.077
AGE 0.228 0.123
5-day intensive care unit follow-up (n = 22)
Maximum leukocyte count during follow-up 0.568 0.006
Maximum CRP during follow-up 0.443 0.039
Age 0.143 0.527
TaBle 3 | soluble urokinase-type plasminogen activator receptor 
(suPar) levels on day five from aneurysmal subarachnoid hemorrhage 
patients (n = 22) in whom there was 5-days’ intensive care unit follow-up 
data and their association with selected clinical conditions.
suPar (ng/ml) Mean sD Median iQr p-Value
Modified Rankin Scale 0.187
0–2 (n = 4) 2.24 0.72 2.18 1.99–2.43
3–6 (n = 18) 2.95 0.81 2.90 2.49–3.70
Delayed cerebral ischemia 
treatment
0.854
Yes (n = 16) 2.80 0.79 2.64 2.18–3.32
No (n = 6) 2.89 1.00 3.12 2.25–3.48
Infection 0.511
Yes (n = 11) 2.97 0.81 3.09 2.60–3.67
No (n = 11) 2.68 0.86 2.46 2.01–3.17
Acute hydrocephalus 0.511
Yes (n = 11) 2.70 0.91 2.64 1.91–3.45
No (n = 11) 2.95 0.77 3.09 2.32–3.39
Mann–Whitney U-test was used.
FigUre 3 | soluble urokinase-type plasminogen activator receptor (suPar) levels for patients with a follow-up of up to 5 days (n = 22). Dots represent 
individual patient values. Regression line is calculated with linear regression. Values are grouped according to favorable (p = 0.584) or non-favorable (p = 0.158) 
neurological outcome.
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between suPAR levels and generally accepted inflammatory 
biomarkers (CRP, leukocyte count). The correlation, however, 
was weak in comparison to previously reported results (35, 40) 
possibly indicating that there are numerous factors influencing 
inflammatory biomarkers and mediators in aSAH. In addition, 
although higher age was associated with poor outcome per  se, 
in our patient cohort, we observed no correlation between age 
and plasma suPAR levels. This finding contradicts the results of 
several previous studies (10, 13, 41, 42). Finally, the low incidence 
(29.8%) of nosocomial infections in our patient cohort may par-
tially explain the observed low plasma suPAR levels.
Even though serum suPAR levels have been shown to be 
elevated in ischemic stroke (43) and in cerebrospinal fluid (CSF) 
following disruption of the blood–brain barrier (44), no marked 
elevation of plasma suPAR was found in patients either diagnosed 
with DCI or acute hydrocephalus. Further analyses will be neces-
sary to clarify potential importance of suPAR release to CSF in 
patients with DCI and acute hydrocephalus. In order to reveal 
the actual role of suPAR as a biomarker or mediator in aSAH, 
it would be worthwhile evaluating the potential value of suPAR 
levels in CSF in diagnosing ventriculitis related to ventriculos-
tomy catheter.
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Our study has some limitations. First, we had some patients 
that were lost to follow-up. In other words, we were not able to 
obtain samples late in the course of the acute illness as patients 
had either died or been transferred to some other health-care 
facility. These patients represent two extremes, i.e., either the best 
or the worst outcome, and this may have altered the results of our 
analysis. Second, our sample size was limited. In particular, only 
four patients with a favorable neurological outcome remained 
in the final analyses on day 5. However, some of our patients 
experienced mild whereas others had very severe presentations 
of aSAH. We followed suPAR levels during the whole ICU stay 
and suPAR levels were constantly low with no high peaks being 
observed. This suggests that aSAH does not induce high suPAR 
levels in plasma or they are depressed by some aspect of the 
treatment, for example, administration of the calcium antagonist. 
Third, our study is a single-center study. Although our unit is a 
tertiary referral hospital with a high patient influx, single-center 
bias is possible. Despite their relatively low numbers, it is of 
interest that those patients with a good neurological outcome 
had remarkably low plasma suPAR levels with a very small SD 
(Figure 2B). Our previous studies have suggested that while high 
suPAR levels may be prognostic for poor outcome, in contrast, a 
low plasma suPAR concentration is predictive of a good outcome 
(11, 45). In the present study, the number of patients is limited, 
but the same phenomenon may apply to aSAH.
cOnclUsiOn
This study reports the first population-based prospective, 
observational results evaluating plasma suPAR concentrations 
in aSAH. Plasma suPAR levels were not associated with neuro-
logical outcome or selected clinical conditions. While suPAR is a 
promising biomarker in several conditions requiring intensive 
care, based on this study, it does not seem to be useful as a prog-
nostic biomarker in patients with aSAH.
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